Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr 15;72(8):2028-35.
doi: 10.1158/0008-5472.CAN-11-4064. Epub 2012 Feb 27.

Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age

Christopher I Li  1 , Elisabeth F Beaber, Mei Tzu Chen Tang, Peggy L Porter, Janet R Daling, Kathleen E Malone
Affiliations

Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age

Christopher I Li et al. Cancer Res. .

Abstract

Depo-medroxyprogesterone acetate (DMPA) is an injectable contraceptive that contains the same progestin as the menopausal hormone therapy regimen found to increase breast cancer risk among postmenopausal women in the Women's Health Initiative clinical trial. However, few studies have evaluated the relationship between DMPA use and breast cancer risk. Here, we conducted a population-based case-control study among 1,028 women ages 20 to 44 years to assess the association between DMPA use and breast cancer risk. Detailed information on DMPA use and other relevant covariates was obtained through structured interviewer-administered in-person questionnaires, and unconditional logistic regression was used to evaluate associations between various aspects of DMPA use and breast cancer risk. We found that recent DMPA use for 12 months or longer was associated with a 2.2-fold [95% confidence interval (CI), 1.2-4.2] increased risk of invasive breast cancer. This risk did not vary appreciably by tumor stage, size, hormone receptor expression, or histologic subtype. Although breast cancer is rare among young women and the elevated risk of breast cancer associated with DMPA appears to dissipate after discontinuation of use, our findings emphasize the importance of identifying the potential risks associated with specific forms of contraceptives given the number of available alternatives.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest:

None of the authors have any potential conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289:3243–53. - PubMed
    1. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12. - PubMed
    1. Frost JJ, Jones RK, Woog V, Singh S, Darroch JE. Occasional Report No 8. New York, NY: The Alan Guttmacher Institute; 2001. Teenage sexual and reproductive behavior in developed countries: Country report for the United States.
    1. Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst. 1987;79:1247–54. - PubMed
    1. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet. 1991;338:833–8. - PubMed

Publication types

Substances